Loading
A phase 1/2 trial of HRS-8080 and Fulvestrant in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT07389733 by Shandong Suncadia Medicine Co., Ltd., with 180 participants planned, started 2026-03-27 and due to reach its primary completion in 2028-12. Interventions recorded: HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet, Fulvestrant injection and Letrozole tablets.
Shares HRS-8080, Fulvestrant, Jiangsu Hengrui Pharmaceuticals, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.